Table 1 Survival ratio of recipient mice after IV-BMT and IBM-BMT of β4GalT-1-deficient BMCs.
BMT methods | Donor BMCs | Recipient mice | Survival ratio (alive/total) | ||||
|---|---|---|---|---|---|---|---|
0* | 5* | 10* | 15* | 60* | |||
IV-BMT | β4GalT-1 −/− | C57BL/6 (wt) | 3/3 | 3/3 | 0/3 | 0/3 | 0/3 |
β4GalT-1 +/− | C57BL/6 (wt) | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | |
β4GalT-1 −/− | β4GalT-1 −/− | 2/2 | 2/2 | 0/2 | 0/2 | 0/2 | |
C57BL/6 (wt) | β4GalT-1 −/− | 3/3 | 3/3 | 3/3 | 3/3 | 3/3 | |
no | C57BL/6 (wt) | 3/3 | 3/3 | 0/3 | 0/3 | 0/3 | |
IBM-BMT | β4GalT-1 −/− | C57BL/6 (wt) | 4/4 | 4/4 | 0/4 | 0/4 | 0/4 |
β4GalT-1 +/− | C57BL/6 (wt) | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 | |
no | C57BL/6 (wt) | 4/4 | 3/4 | 0/4 | 0/4 | 0/4 | |
IV-BMT | β4GalT-1 −/− | NOD/SCID | 4/4 | 4/4 | 0/4 | 0/4 | |
β4GalT-1 +/− | NOD/SCID | 4/4 | 4/4 | 4/4 | 4/4 | ||
no | NOD/SCID | 2/2 | 1/2 | 0/2 | 0/2 | ||
